Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy—Factors associated with advanced fibrosis

Abstract

Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy-Factors associated with advanced fibrosis.OGIONWO JERKEMAN, ANNA; Westin, Johan; Lagging, Martin; Norkrans, Gunnar; Lidman, Christer; Frimand, Jan; Simonsberg, Christian; Kakko, Johan; Widell, Anders; Björkman, Per Link to publication Citation for published version (APA): Jerkeman, A., Westin, J., Lagging, M., Norkrans, G., Lidman, C., Frimand, J., ... Björkman, P. (2014). Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy-Factors associated with advanced fibrosis. Scandinavian Journal of Infectious Diseases, 46(5), 340-347. DOI: 10.3109/00365548.2013.879994 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal

Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy

“…In addition, they have a higher prevalence of factors that both increase overall morbidity and mortality (such as HIV and HBV co‐infection, tobacco and alcohol use); factors that also are associated with progression of HCV related liver fibrosis . We have recently reported a high prevalence of liver fibrosis in OST recipients with chronic hepatitis C . The findings from the current study suggest that if the excess mortality during active injection drug use can be reduced, chronic liver disease may emerge as an increasingly important health problem among PWID.…”

Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden

“…Treatment uptake of HCV in active PWID has historically been low in Sweden and treatment in the OAT population also limited. Previous data, before the DAA era, showed that the overall lifetime uptake of HCV treatment among PWID on OAT was between 1 and 6% [ 34 – 36 ]. However, an observational study with data from the Swedish Prescribed Drug Registers noted an estimated cumulative DAA treatment uptake of 28% among OAT participants between 2014 and 2017 [ 37 ].…”